Therapeutic Vaccines for Herpesviruses

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2024 May 1

PMID 38690731

Authors

Jeffrey I Cohen

Affiliations

Soon will be listed here.

Abstract

Herpesviruses establish latent infections, and most reactivate frequently, resulting in symptoms and virus shedding in healthy individuals. In immunocompromised patients, reactivating virus can cause severe disease. Persistent EBV has been associated with several malignancies in both immunocompromised and nonimmunocompromised persons. Reactivation and shedding occur with most herpesviruses, despite potent virus-specific antibodies and T cell immunity as measured in the blood. The licensure of therapeutic vaccines to reduce zoster indicates that effective therapeutic vaccines for other herpesviruses should be feasible. However, varicella-zoster virus is different from other human herpesviruses in that it is generally only shed during varicella and zoster. Unlike prophylactic vaccines, in which the correlate of immunity is antibody function, T cell immunity is the correlate of immunity for the only effective therapeutic herpesvirus vaccine-zoster vaccine. While most studies of therapeutic vaccines have measured immunity in the blood, cellular immunity at the site of reactivation is likely critical for an effective therapeutic vaccine for certain viruses. This Review summarizes the status of therapeutic vaccines for herpes simplex virus, cytomegalovirus, and Epstein-Barr virus and proposes approaches for future development.

Citing Articles

High IgG titers against EBV glycoprotein 42 correlate with lower risk of nasopharyngeal carcinoma.

Warner B, Shair K J Clin Invest. 2025; 135(4).

PMID: 39959976 PMC: 11827836. DOI: 10.1172/JCI189207.

Oral Pathogens' Substantial Burden on Cancer, Cardiovascular Diseases, Alzheimer's, Diabetes, and Other Systemic Diseases: A Public Health Crisis-A Comprehensive Review.

Murray P, Coffman J, Garcia-Godoy F Pathogens. 2025; 13(12.

PMID: 39770344 PMC: 11677847. DOI: 10.3390/pathogens13121084.

Intra-host genomic diversity and integration landscape of human tissue-resident DNA virome.

Pyoria L, Pratas D, Toppinen M, Simmonds P, Hedman K, Sajantila A Nucleic Acids Res. 2024; 52(21):13073-13093.

PMID: 39436041 PMC: 11602146. DOI: 10.1093/nar/gkae871.

Viral etiologies of acute liver failure.

McSteen B, Ying X, Lucero C, Jesudian A World J Virol. 2024; 13(3):97973.

PMID: 39323454 PMC: 11401000. DOI: 10.5501/wjv.v13.i3.97973.

Is Essential for Herpes Simplex Virus-1 Virulence In Vivo but Is Dispensable for Induction of Host-Protective Immunity.

Tongmuang N, Krishnan M, Connor V, Crump C, Jensen L Vaccines (Basel). 2024; 12(8).

PMID: 39203963 PMC: 11359923. DOI: 10.3390/vaccines12080837.

References

Bernstein D, Flechtner J, McNeil L, Heineman T, Oliphant T, Tasker S . Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease. Vaccine. 2019; 37(26):3443-3450. DOI: 10.1016/j.vaccine.2019.05.009. View

KERN A, SCHIFF B . VACCINE THERAPY IN RECURRENT HERPES SIMPLEX. Arch Dermatol. 1964; 89:844-5. DOI: 10.1001/archderm.1964.01590300072021. View

Chentoufi A, Dhanushkodi N, Srivastava R, Prakash S, Coulon P, Zayou L . Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back. Front Immunol. 2022; 13:849515. PMC: 9082490. DOI: 10.3389/fimmu.2022.849515. View

Taylor G, Long H, Brooks J, Rickinson A, Hislop A . The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol. 2015; 33:787-821. DOI: 10.1146/annurev-immunol-032414-112326. View

Jenks J, Goodwin M, Permar S . The Roles of Host and Viral Antibody Fc Receptors in Herpes Simplex Virus (HSV) and Human Cytomegalovirus (HCMV) Infections and Immunity. Front Immunol. 2019; 10:2110. PMC: 6742691. DOI: 10.3389/fimmu.2019.02110. View

Skinner G, Turyk M, Benson C, Wilbanks G, Heseltine P, Galpin J . The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial. Med Microbiol Immunol. 1997; 186(1):31-6. DOI: 10.1007/s004300050043. View

Kutinova L, Benda R, Kalos Z, Dbaly V, Votruba T, KVICALOVA E . Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine. 1988; 6(3):223-8. DOI: 10.1016/0264-410x(88)90215-0. View

Savoldo B, Cubbage M, Durett A, Goss J, Huls M, Liu Z . Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002; 168(2):909-18. DOI: 10.4049/jimmunol.168.2.909. View

Peng S, Ferrall L, Gaillard S, Wang C, Chi W, Huang C . Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody. mBio. 2021; 12(1). PMC: 7845631. DOI: 10.1128/mBio.03224-20. View

10.

Straus S, Corey L, Burke R, Savarese B, Barnum G, Krause P . Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 1994; 343(8911):1460-3. DOI: 10.1016/s0140-6736(94)92581-x. View

11.

Dropulic L, Cohen J . The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines. 2012; 11(12):1429-40. PMC: 3593236. DOI: 10.1586/erv.12.129. View

12.

de Franca T, Carvalho A, Gomes V, Gueiros L, Porter S, Leao J . Salivary shedding of Epstein-Barr virus and cytomegalovirus in people infected or not by human immunodeficiency virus 1. Clin Oral Investig. 2011; 16(2):659-64. DOI: 10.1007/s00784-011-0548-5. View

13.

de Bruyn G, Vargas-Cortez M, Warren T, Tyring S, Fife K, Lalezari J . A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine. 2005; 24(7):914-20. DOI: 10.1016/j.vaccine.2005.08.088. View

14.

Shin H, Iwasaki A . A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature. 2012; 491(7424):463-7. PMC: 3499630. DOI: 10.1038/nature11522. View

15.

Dave V, Richert-Spuhler L, Arkatkar T, Warrier L, Pholsena T, Johnston C . Recurrent infection transiently expands human tissue T cells while maintaining long-term homeostasis. J Exp Med. 2023; 220(9). PMC: 10267593. DOI: 10.1084/jem.20210692. View

16.

Koelle D, Liu Z, McClurkan C, Cevallos R, Vieira J, Hosken N . Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. Proc Natl Acad Sci U S A. 2003; 100(22):12899-904. PMC: 240716. DOI: 10.1073/pnas.2131705100. View

17.

Harbecke R, Cohen J, Oxman M . Herpes Zoster Vaccines. J Infect Dis. 2021; 224(12 Suppl 2):S429-S442. PMC: 8482024. DOI: 10.1093/infdis/jiab387. View

18.

Koelle D, Chen H, GAVIN M, Wald A, Kwok W, Corey L . CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol. 2001; 166(6):4049-58. DOI: 10.4049/jimmunol.166.6.4049. View

19.

Bjornevik K, Cortese M, Healy B, Kuhle J, Mina M, Leng Y . Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022; 375(6578):296-301. DOI: 10.1126/science.abj8222. View

20.

Posavad C, Remington M, Mueller D, Zhao L, Magaret A, Wald A . Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol. 2010; 184(6):3250-9. PMC: 2877513. DOI: 10.4049/jimmunol.0900722. View